Literature DB >> 33499035

Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Acute Kidney Injury in Emergency Medical Admissions.

Athanasios Feidakis1, Maria-Rosa Panagiotou1, Emmanouil Tsoukakis1, Dimitra Bacharaki1, Paraskevi Gounari1, Petros Nikolopoulos1, Katerina P Marathias2, Sophia Lionaki1, Demetrios Vlahakos1.   

Abstract

BACKGROUND: Acute kidney injury (AKI) has been observed in up to 20% of adult hospital admissions. Sepsis, diarrhea and heart failure, all causing reduced effective volume, are considered risk factors for AKI, especially among patients treated with medications that block the Renin-Angiotensin System (RAS), such as angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB). We aimed to determine the incidence of acute kidney injury (AKI) in emergency medical admissions in relation to the use and dosage of ACEi/ARB.
METHODS: A single-center observational study conducted in 577 consecutive medical admissions via the Emergency Room (ER) at a University General Hospital in Athens, Greece, between June and July 2018. Patients with incomplete medical records, discharged within 24 h, maintained on chronic renal replacement therapy, admitted to the Cardiology Department or the ICU were excluded. Thus, a total of 309 patients were finally included in this analysis.
RESULTS: We compared 86 (28%) patients who presented in the ER with AKI (AKIGroup) with 223 (72%) patients without AKI (non-AKI Group) at the time of admission. Patients in the AKI Group were more frequently male (58% vs. 46%, p = 0.06), with a higher frequency of diarrhea (16% vs. 6%, p = 0.006), edema (15% vs. 6%, p = 0.014) and lower systolic blood pressure (120 (107-135) vs. 126 (113-140), p = 0.007) at presentation, despite higher prevalence of hypertension (64% vs. 47%, p = 0.006). Overall, ACEi/ARB were more likely to have been prescribed in the AKI Group than in the non-AKI Group (49% vs. 28%, p = 0.001). Interestingly, AKI was more frequently observed in patients treated with the target or above target dosage of ACEi/ARB, but not in those receiving lower than the recommended dosage.
CONCLUSION: The risk of AKI in emergency medical admissions is higher among users of ACEIs/ARB at target or above target dosages. Physicians should adjust RAS blockade according to estimated Glomerular Filtration Rate (eGFR) and advise their patients to withhold ACEi/ARB in cases of acute illness.

Entities:  

Keywords:  acute kidney injury; angiotensin receptor blockers; angiotensin-converting enzyme inhibitors; emergency medical admission

Year:  2021        PMID: 33499035      PMCID: PMC7865425          DOI: 10.3390/jcm10030412

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  21 in total

1.  Acute changes in glomerular filtration rate with renin-angiotensin system (RAS) inhibition: clinical implications.

Authors:  Matthew R Weir
Journal:  Kidney Int       Date:  2017-03       Impact factor: 10.612

2.  Acute kidney injury and mortality in hospitalized patients.

Authors:  Henry E Wang; Paul Muntner; Glenn M Chertow; David G Warnock
Journal:  Am J Nephrol       Date:  2012-04-02       Impact factor: 3.754

Review 3.  Acute kidney injury and chronic kidney disease as interconnected syndromes.

Authors:  Lakhmir S Chawla; Paul W Eggers; Robert A Star; Paul L Kimmel
Journal:  N Engl J Med       Date:  2014-07-03       Impact factor: 91.245

4.  Association between exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prior to septic shock and acute kidney injury.

Authors:  B Suberviola; E Rodrigo; A González-Castro; M Serrano; M Heras; Á Castellanos-Ortega
Journal:  Med Intensiva       Date:  2016-10-27       Impact factor: 2.491

5.  Characteristics and Outcomes of Patients Discharged Home from an Emergency Department with AKI.

Authors:  Rey R Acedillo; Ron Wald; Eric McArthur; Danielle Marie Nash; Samuel A Silver; Matthew T James; Michael J Schull; Edward D Siew; Michael E Matheny; Andrew A House; Amit X Garg
Journal:  Clin J Am Soc Nephrol       Date:  2017-07-20       Impact factor: 8.237

Review 6.  Drug dosing adjustments in patients with chronic kidney disease.

Authors:  Myrna Y Munar; Harleen Singh
Journal:  Am Fam Physician       Date:  2007-05-15       Impact factor: 3.292

7.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

Authors:  Jackson T Wright; Jeff D Williamson; Paul K Whelton; Joni K Snyder; Kaycee M Sink; Michael V Rocco; David M Reboussin; Mahboob Rahman; Suzanne Oparil; Cora E Lewis; Paul L Kimmel; Karen C Johnson; David C Goff; Lawrence J Fine; Jeffrey A Cutler; William C Cushman; Alfred K Cheung; Walter T Ambrosius
Journal:  N Engl J Med       Date:  2015-11-09       Impact factor: 91.245

8.  Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study.

Authors:  Kathryn E Mansfield; Dorothea Nitsch; Liam Smeeth; Krishnan Bhaskaran; Laurie A Tomlinson
Journal:  BMJ Open       Date:  2016-12-21       Impact factor: 2.692

9.  Acute kidney injury and infections in patients taking antihypertensive drugs: a self-controlled case series analysis.

Authors:  Kathryn E Mansfield; Ian J Douglas; Dorothea Nitsch; Sara L Thomas; Liam Smeeth; Laurie A Tomlinson
Journal:  Clin Epidemiol       Date:  2018-01-30       Impact factor: 4.790

10.  ACE inhibitor and angiotensin receptor-II antagonist prescribing and hospital admissions with acute kidney injury: a longitudinal ecological study.

Authors:  Laurie A Tomlinson; Gary A Abel; Afzal N Chaudhry; Charles R Tomson; Ian B Wilkinson; Martin O Roland; Rupert A Payne
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

View more
  1 in total

1.  The effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in critically ill patients with acute kidney injury: An observational study using the MIMIC database.

Authors:  Xu Zhu; Jing Xue; Zheng Liu; Wenjie Dai; Jingsha Xiang; Hui Xu; Qiaoling Zhou; Quan Zhou; Xinran Wei; Wenhang Chen
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.